News

According to the company, treating rheumatoid arthritis at this critical early phase might prevent irreversible damage to joints and long-term disability. RoACTEMRA is the first interleukin-6 (IL-6) receptor

"COTI-2 is selectively active in in vivo and in vitro models with abnormal TP53. This is very exciting as TP53 is one of the "big three" of critically

Upon payment of an option exercise fee to AnaptysBio, Momenta has received worldwide rights to therapeutic antibodies against a target selected based upon the anti-inflammatory effects of IVIg.

Under the Alliance Agreement, each company will contribute its specific expertise and resources with the objective of advancing biodefense products to be agreed to under individual product plans.

The solution, Just-In-Time (JIT), addresses inefficiencies in the oncology drug-development process, which fails to match the increasing molecular stratification of cancers. The evaluation represents a key collaboration between

Last month, Par received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for dexmedetomidine HCl injection, which is indicated for sedation

The company’s lead next-generation immunotoxin compound, MT-3724, is capable of forcing internalization against the CD20 B-cell surface marker and inducing direct cell death via ribosome inactivation in CD20-expressing

The partnership will support research through the Collaborative Center for Drug Research (CCDR) as well as improve the spirit of discovery and exploration in the field of neuroscience

Initial phase of the new facility is scheduled to be opened within eight weeks, and it will be built and managed by British military engineers and medical staff.